KR20180031247A - Health supplementary food containing lactic acid bacteria - Google Patents
Health supplementary food containing lactic acid bacteria Download PDFInfo
- Publication number
- KR20180031247A KR20180031247A KR1020160119444A KR20160119444A KR20180031247A KR 20180031247 A KR20180031247 A KR 20180031247A KR 1020160119444 A KR1020160119444 A KR 1020160119444A KR 20160119444 A KR20160119444 A KR 20160119444A KR 20180031247 A KR20180031247 A KR 20180031247A
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- lactic acid
- acid bacteria
- weight
- bifidobacterium
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 241000894006 Bacteria Species 0.000 title claims abstract description 83
- 239000004310 lactic acid Substances 0.000 title claims abstract description 49
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 49
- 235000013305 food Nutrition 0.000 title abstract description 10
- 230000036541 health Effects 0.000 title abstract description 7
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 16
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 16
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 12
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 11
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 11
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 11
- 239000011710 vitamin D Substances 0.000 claims abstract description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 11
- 229940046008 vitamin d Drugs 0.000 claims abstract description 11
- 239000011701 zinc Substances 0.000 claims abstract description 11
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 11
- 235000016804 zinc Nutrition 0.000 claims abstract description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 10
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 10
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 10
- 235000021277 colostrum Nutrition 0.000 claims abstract description 10
- 210000003022 colostrum Anatomy 0.000 claims abstract description 10
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 9
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 9
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 9
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 9
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 9
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 9
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 235000004554 glutamine Nutrition 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 229960002743 glutamine Drugs 0.000 claims description 5
- 239000004382 Amylase Substances 0.000 claims description 3
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 235000019418 amylase Nutrition 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 27
- 206010010774 Constipation Diseases 0.000 abstract description 5
- 210000000936 intestine Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002550 fecal effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 3
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 102000006995 beta-Glucosidase Human genes 0.000 description 3
- 108010047754 beta-Glucosidase Proteins 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000186610 Lactobacillus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-UHFFFAOYSA-N 0.000 description 1
- QSUILVWOWLUOEU-GOVZDWNOSA-N 4-nitrophenyl beta-D-glucuronide Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 QSUILVWOWLUOEU-GOVZDWNOSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A23Y2220/00—
-
- A23Y2300/00—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 유산균 함유 건강보조식품에 관한 것으로, 더욱 상세하게는 11종의 혼합 유산균과 함께, 바실러스 서브틸러스, 프락토올리고당, 갈락토올리고당, 초유, 글루타민, 비타민 A, 비타민 D, 아연 등을 포함하여 장내 환경을 개선하는 유산균 함유 건강보조식품에 관한 것이다. The present invention relates to a health supplement containing lactic acid bacteria. More particularly, the present invention relates to a health supplement containing lactic acid bacteria. More specifically, the present invention relates to a health supplement containing lactic acid bacteria, To a health supplement containing lactic acid bacteria which improves intestinal environment.
우리의 장내에 존재하는 장내 세균은 유익균과 유해균으로 나눌 수 있으며 이들의 종류는 약 2000여 종으로 균수는 100조 정도에 이른다. 이들은 증식을 계속하면서도 서로 다른 균의 증식을 항상 견제하고 있기 때문에 장내 환경의 급격한 변화가 없는 한 대체로 일정한 비율을 유지하며 장내에 동시에 살고 있다. 유해균과 유익균은 서로 경쟁적인 관계이다. 따라서 어느 쪽이 우월 하느냐에 따라 장이 건강한지 아니면 자주 문제가 발생하는 지가 결정되게 된다. 장내 세균의 균형이 파괴되어 유해균이 많아지거나 또는 유익균이 너무 적어지면 장의 기능이 떨어지고, 만성적 설사, 복부 통증, 팽만감, 냄새, 영양결핍, 패혈증, 쇼크 등 여러 증상이 나타난다. 유해균은 주로 단백질을 분해시켜 인체에 해로운 암모니아나 유화수소, 아민, 페놀, 인돌 등의 악취가 나거나 독성이 강한 물질을 생성한다. 이들 유해물질은 장점막을 지나 혈액 속으로 스며들어 전신에 퍼질 수 있으며, 이로 인해 면역계에도 심각한 문제를 유발할 수 있다. 또한, 장내 염증성 질환이나 설사를 일으키기도 한다.Intestinal bacteria present in our intestines can be divided into useful bacteria and harmful bacteria, and about 2000 kinds of them are bacteria. They continue to multiply, but because they constantly check for the growth of different bacteria, they usually live in the intestines at a constant rate, unless there is a rapid change in the intestinal environment. The harmful bacteria and the beneficial bacteria are in a competitive relationship. Thus, depending on which one is superior, it is determined whether the intestines are healthy or frequently occur. If the balance of intestinal bacteria is destroyed and the number of harmful bacteria is increased or too much of the beneficial bacteria is decreased, the function of the intestines will be lowered and various symptoms such as chronic diarrhea, abdominal pain, bloating, smell, nutritional deficiency, sepsis and shock will appear. The harmful bacteria mainly decompose the protein and produce odorous or toxic substances such as ammonia, hydrogen sulfide, amine, phenol, and indole that are harmful to human body. These harmful substances can penetrate into the blood through the intestinal mucosa and spread to the whole body, which can cause serious problems in the immune system. It can also cause intestinal inflammatory disease or diarrhea.
장내 유익균으로 알려진 유산균은 장내 유해균과 부패균의 증식을 억제하여 각종 장질환의 원인물질인 암모니아, 인돌, 황화수소 등 장내 부패 산물의 생성을 막고 장내에 작용하는 항생 물질을 생성하여 장내 세균총을 정상적으로 만들어 준다. 또한, 생체의 면역기전(대식세포, 임파구) 활성화와 혈액 내 항체의 생성을 촉진하여 면역성을 좋게 할 뿐만 아니라 장내 활성 산소와 발암물질을 생성하는 유해균의 생육을 억제하거나 사멸을 유도하여 항염작용을 하는 것으로 보고되고 있으며 비타민 K, 수용성 비타민 B군(B1, B2, B6, B12) 등을 합성하여 장의 영양 상태를 좋게 만든다. 특히 Lactobacillus sp.에 속하는 유산균 배양액을 사람이나 실험용 동물에게 음용시켰을 때 항균 활성을 나타내며 스트레스성 변비나 설사를 개선하고 콜레스테롤 합성을 억제하며 알레르기 개선이나 피부미용에도 효과적이다. 특히 헬리코박터 파일로리를 억제하는 효과가 있음이 다수 발표되었고 현재 국내에서도 헬리코박터 파이로리균를 억제하는 유산균을 발효유 및 다양한 건강기능식품으로 개발되거나 판매되고 있다.Lactic acid bacteria, known as beneficial bacteria in the intestines, inhibits the growth of harmful bacteria and coliform bacteria in the intestines and prevents the production of intestinal decay products such as ammonia, indole, and hydrogen sulfide, which cause various enteric diseases, and produces intestinal bacteria . In addition, it stimulates the immune system (macrophage, lymphocyte) of the living body and promotes the production of antibody in the blood, thereby improving the immune system. In addition, it inhibits the growth of the intestinal active oxygen and carcinogenic substances, Vitamin K and water soluble vitamin B group (B1, B2, B6, B12) are synthesized to improve the nutritional status of the intestines. Especially Lactobacillus sp. Cultures belonging to Lactobacillus sp. Have antibacterial activity when they are administered to humans or laboratory animals. They are also effective in improving stress constipation and diarrhea, inhibiting cholesterol synthesis, improving allergy and skin beauty. Especially, it has been reported that there are many effects that suppress Helicobacter pylori. Currently, lactic acid bacteria that inhibit Helicobacter pylori are also developed or sold as fermented milk and various health functional foods in Korea.
그러나 이러한 유산균은 단독으로 섭취시 그 효과가 크지 않았는바, 본 발명은 혼합유산균과 기타의 성분을 이용하여 장내 환경을 개선하고자 하는 것이다.However, since the effect of the lactic acid bacteria alone on ingestion thereof is not great, the present invention intends to improve the intestinal environment by using mixed lactic acid bacteria and other ingredients.
따라서, 본 발명의 목적은 11종의 혼합 유산균, 바실러스 서브틸러스, 프락토올리고당, 갈락토올리고당, 초유, 글루타민, 비타민 A, 비타민 D, 아연을 함유하는 유산균 함유 건강보조식품을 제공함으로써, 장내 환경을 개선하는 것이다.Accordingly, an object of the present invention is to provide a health supplement containing lactic acid bacteria containing 11 kinds of mixed lactic acid bacteria, Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, To improve the environment.
상기한 목적을 달성하기 위한 본 발명의 유산균 함유 건강보조식품은, 혼합 유산균, 바실러스 서브틸러스(Bacillus subtillis), 프락토올리고당, 갈락토올리고당, 초유, 글루타민, 비타민 A, 비타민 D 및 아연을 포함하며, 상기 혼합 유산균은 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)인 것을 특징으로 한다.In order to achieve the above object, the present invention provides a health supplement containing lactic acid bacteria, which comprises a mixed lactic acid bacterium, Bacillus subtillis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc Wherein the mixed lactic acid bacteria are selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracase, But not limited to, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis Bifidobacterium lactis) and Bifidobacterium bifidum.
상기 혼합 유산균 10~20중량%, 바실러스 서브틸러스 0.1~1중량%, 프락토올리고당 10~15중량%, 갈락토올리고당 10~15중량%, 초유 20~30중량%, 비타민 A 0.01~0.05중량%, 비타민 D 0.0001~0.01중량%, 아연 0.1~0.5중량% 및 잔여분의 글루타민을 포함하는 것을 특징으로 한다. 10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% by weight of colostrum, 0.01 to 0.05% by weight of vitamin A, 10 to 20% by weight of said mixed lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, %, Vitamin D 0.0001 ~ 0.01 wt%, zinc 0.1 ~ 0.5 wt%, and the remainder of glutamine.
상기 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)의 균수는 각각 1.0×1011cfu/g~5.0×1011cfu/g인 것을 특징으로 한다. Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus spp. Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium lactis, The number of bacteria of Bifidobacterium bifidum is 1.0 × 10 11 cfu / g to 5.0 × 10 11 cfu / g, respectively.
아밀라아제 0.5~3중량%, 리파아제 0.5~3중량%, 프로테아제 0.5~3중량%, 락토아제 0.5~3중량%를 더 포함하는 것을 특징으로 한다.0.5 to 3% by weight of amylase, 0.5 to 3% by weight of lipase, 0.5 to 3% by weight of protease and 0.5 to 3% by weight of lactose.
본 발명에 의하면, 장내 환경을 개선하고, 쾌변을 유도하며, 변비를 해소하는데 도움을 주는 효과가 있다.INDUSTRIAL APPLICABILITY According to the present invention, there is an effect of improving the intestinal environment, inducing a pleasant state, and helping to relieve constipation.
도 1은 본 발명에 의한 실험예 1의 결과를 나타낸 그래프.1 is a graph showing the results of Experimental Example 1 according to the present invention.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 혼합 유산균, 바실러스 서브틸러스(Bacillus subtillis), 프락토올리고당, 갈락토올리고당, 초유, 글루타민, 비타민 A, 비타민 D 및 아연을 포함하며, 상기 혼합 유산균은 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)인 것을 특징으로 함으로써, 장내 환경을 개선하여 쾌변을 유도하고, 변비를 개선하는 효과를 갖는다.The present invention relates to a pharmaceutical composition comprising lactic acid bacteria, Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, wherein the mixed lactic acid bacteria are Lactobacillus plantarum ), Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus reuteri, Lactobacillus spp. Bifidobacterium longis, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium bifidum may be used in the present invention. Examples of the Bifidobacterium bifidum include Bacillus subtilis, Bacillus subtilis, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, It is possible to improve the intestinal environment to induce a pleasant state and to have an effect of improving constipation .
본 발명에서 장내 환경의 개선이란 장내 유산균의 총균수를 늘리고, 장내 유해 효소의 활성을 억제하는 것을 의미한다.In the present invention, improvement of the intestinal environment means increasing the total number of intestinal lactic acid bacteria and inhibiting the activity of intestinal harmful enzymes.
먼저, 유산균은 장내 유익균으로서 충분히 공지되어 있으나, 유산균을 단독으로 사용할 경우 그 효과가 미미하다. 따라서, 본 발명은 장내 환경개선에 도움을 주는 11종의 혼합 유산균을 사용함으로써, 다양한 생리활성작용을 갖도록 하는 것이다. 여기서 상기 각 유산균은 배양 후, 그 배양액을 동결건조하여서 되는 파우더 형태이거나, 상기 파우더를 코팅 또는 마이크로 캡슐 처리한 형태일 수 있는바, 이를 반드시 제한하는 것은 아니다. 또한, 시판되고 있는 분말 형태의 유산균을 구입하여 사용하는 것도 가능하다. 여기서, 상기 동결건조, 코팅 및 마이크로 캡슐 처리는 이 기술이 속하는 분야에서 공지된 사항이므로, 이에 대한 설명은 생략한다. First, the lactic acid bacteria are sufficiently known as beneficial bacteria in the intestines, but the effect is insignificant when the lactic acid bacteria are used alone. Accordingly, the present invention uses various kinds of mixed lactic acid bacteria that help improve the intestinal environment, so as to have various physiological activities. Herein, each of the lactic acid bacteria may be in the form of a powder obtained by lyophilizing the culture solution after culturing, or may be in the form of coating or microcapsulating the powder, but the present invention is not limited thereto. It is also possible to purchase commercially available lactic acid bacteria in powder form. Here, the lyophilization, coating, and microcapsule treatment are well known in the art, and a description thereof will be omitted.
상기 혼합 유산균에 대해 간략히 설명하면 다음과 같다.Hereinafter, the mixed lactic acid bacteria will be briefly described.
먼저, 상기 락토바실러스 플란타럼(Lactobacillus plantarum)은 유산균의 증식, 유해균의 억제 및 배변활동에 도움을 주는 작용을 한다. First, the Lactobacillus plantarum has a function to promote the growth of lactic acid bacteria, inhibition of harmful bacteria, and defecation activity.
상기 락토바실러스 애시도필러스(Lactobacillus acidophilus)는 복부, 담즙, 그리고 여러 소장 등의 매우 높은 산성 환경에서도 생존력이 뛰어나며, 오랜 기간 장내에서 살아 있으면서 해로운 박테리아의 성장을 억제시키는 작용을 한다.The Lactobacillus acidophilus is highly viable in very high acidic environments such as the abdomen, bile and several small intestines, and acts to inhibit the growth of harmful bacteria while living in the intestines for a long time.
상기 락토바실러스 람노서스(Lactobacillus rhamnosus)는 강한 산성의 환경에서도 생존력이 뛰어나, 오랜 기간 소화기간에서 살아 있으면서 유해균의 성장을 억제시시키는 작용을 한다. The Lactobacillus rhamnosus is excellent in survival ability even in a strong acidic environment, and is active in the digestion period for a long time and inhibits the growth of harmful bacteria.
상기 락토바실러스 카제이(Lactobacillus casei)는 산이나 열에 강하며, 락토비실러스 애시도필러스의 성장에 도움을 준다. 또한, 인체 내 소화액에 의해 사멸되지 않고 소장까지 가서 소장 내 균총을 정상화시키고, 유당불내증을 줄여주며, 소화작용을 돕는 작용을 한다. The Lactobacillus casei is resistant to acid or heat and helps to grow Lactobacillus ashidophilus. In addition, it does not die by the digestive juice in the body, it goes to the small intestine, normalizes the intestinal flora, reduces intolerance of lactose, and helps digestion.
상기 락토바실러스 파라카제이(Lactobacillus paracasei)은 강한 산성에서도 생존력이 뛰어나며, 위장 내 유해균의 작용을 억제하는 작용을 한다. The above-mentioned Lactobacillus paracasei is excellent in viability even in strong acidity, and acts to inhibit the action of harmful bacteria in the stomach.
상기 락토바실러스 루테리(Lactobacillus reuteri)는 장벽에 강하게 흡착하여 지속적으로 생장하면서 항균물질을 분비하여 유해균을 무력화시키는 작용을 하는 것으로, 장내 총 유산균수를 증가시켜준다.The Lactobacillus reuteri is strongly adsorbed on the barrier and continuously grows to secrete an antimicrobial substance to neutralize harmful bacteria, thereby increasing the total number of lactic acid bacteria in the intestines.
상기 락토바실러스 살리바리우스(Lactobacillus salivarius)는 병원성 세균인 대장균, 황색포도상구균, 살모넬라균 등에 항균작용을 한다.The Lactobacillus salivarius has antibacterial activity against pathogenic bacteria such as Escherichia coli, Staphylococcus aureus and Salmonella.
상기 비피도박테리움 롱검(Bifidobacterium longum)은 위산이나 펩신, 담즙산염에 높은 저항력을 가지고 있으며, 장 점착력이 우수한 특징이 있다.The Bifidobacterium longum has high resistance to gastric acid, pepsin and bile acid, and is excellent in long-term adhesion.
상기 비피도박테리움 브레브(Bifidobacterium breve)는 대장균의 억제, 세균성 설사에 도움을 주며, 성인 알레르기 및 아토피 피부염을 완화시키는 작용을 한다. The Bifidobacterium breve is effective in suppressing E. coli, bacterial diarrhea, and alleviating adult allergies and atopic dermatitis.
상기 비피도박테리움 락티스(Bifidobacterium lactis)는 면역력을 강화하고, 소화력을 개선해주는 유산균으로, 장과 결장에 서식하여 불필요한 물질들을 없애 주는 반면, 비타민과 미네랄은 흡수하는 작용을 한다.Bifidobacterium lactis (Bifidobacterium lactis) is a lactic acid bacterium that enhances immunity and improves digestive power. It absorbs unnecessary substances in the intestines and colon, while it absorbs vitamins and minerals.
상기 비피도박테리움 비피덤(Bifidobacterium bifidum)는 장 내의 마이크로플로라(미소 식물)를 유지해주고, 소화를 촉진하며, 대장균 감염 및 염증의 생성을 저하시키는 작용을 한다.The Bifidobacterium bifidum maintains microflora in the intestines, promotes digestion, and reduces the production of E. coli infection and inflammation.
즉, 상기와 같은 11종의 혼합 유산균은 강한 산성의 환경에서도 살아남아, 위, 장 등 각종 소화기간에 서식하여 유해균의 서식을 억제하고, 유익균의 서식을 도와 장내 환경을 개선해 준다.That is, the above-mentioned 11 types of mixed lactic acid bacteria survive in a strong acidic environment and inhibit the habitat of harmful bacteria by living in various gastrointestinal organs such as stomach and intestines, and help the form of beneficial bacteria and improve intestinal environment.
또한, 본 발명은 혼합 유산균 이외에도 바실러스 서브틸러스(Bacillus subtillis), 프락토올리고당, 갈락토올리고당, 초유, 글루타민, 비타민 A, 비타민 D, 아연을 포함함으로써, 유산균의 증식을 돕는 것은 물론, 쾌변을 유도하고, 숙변을 제거한다.In addition to the mixed lactic acid bacteria, the present invention includes not only Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, Induce, and remove succumbing.
먼저, 상기 바실러스 서브틸러스는 생명력이 강해 대장까지 사멸되지 않는 균으로, 대장에서 장에 붙은 숙변을 분해하고, 쾌변을 돕는 역할을 하여 혼합 유산균과 함께 장내 환경을 개선해준다. 상기 바실러스 서브틸러스 역시 바실러스 서브틸러스를 배양하고, 그 배양액을 동결건조하여서 되는 파우더 형태의 것일 수 있다.First, the Bacillus subtilis is a bacterium that does not kill to the large intestine due to its strong vitality. It also plays a role in helping the pleasure of the intestines in the large intestine and improves intestinal environment together with mixed lactic acid bacteria. The Bacillus subtilis may also be in the form of a powder obtained by culturing Bacillus subtilis and lyophilizing the culture.
상기 프락토올리고당(fructooligosaccharide)과 상기 갈락토올리고당(Galactooligosaccharide)은 대부분 장 내 균에 의해 발효되는바, 발효된 성분이 장 내 환경을 산성화시켜주고, 장 내 균이 사용할 수 있는 먹이가 되어, 장내세균인 비피더스균을 증식시켜 주는 역할을 한다. 따라서, 상기 혼합 유산균과 함께 복용시 유산균의 먹이가 되어 유익균의 총균수를 현저히 늘려준다. 다만, 상기 프락토올리고당은 산성 조건에서의 안정성이 좋지 못한바, 산성 조건에서 안정적인 갈락토올리고당과 균에 의한 발효가 용이한 프락토올리고당을 함께 사용함으로써, 위, 소장, 대장의 전 소화기관에서 안정적으로 작용할 수 있도록 하는 것이다. Since the fructooligosaccharide and the galactooligosaccharide are mostly fermented by intestinal bacteria, the fermented ingredient acidifies the intestinal environment and becomes a food which can be used by intestinal bacteria, It plays a role in propagating the bacterium Bifidus. Therefore, when taken together with the mixed lactic acid bacteria, it becomes a food of the lactic acid bacteria and significantly increases the total number of beneficial bacteria. However, since the fructooligosaccharide has poor stability in an acidic condition, stable galacto-oligosaccharides and fructooligosaccharides, which are easily fermented by bacteria, are used together in an acidic condition, So that they can operate stably.
그리고 상기 초유는 단백질과 무기질이 많아 면역력에 도움을 주는 성분이고, 상기 글루타민은 단백질을 구성하는 아미노산의 일종으로 면역체계의 약화를 막아주고, 단백질 노폐물을 제거해주는 성분으로, 유산균과 함께 섭취시 그 흡수율이 더욱 높아진다.In addition, the colostrum is a component that helps immunity due to a large amount of proteins and minerals. The glutamine is a kind of amino acid that constitutes a protein. It blocks the weakening of the immune system and removes protein waste. The absorption rate is further increased.
또한, 상기 비타민 A, 비타민 D 및 아연은 인체 건강유지를 위한 필수영양소로서, 유산균과 함께 섭취하여 그 흡수율을 높이는 것은 물론, 섭취자의 건강유지를 돕는 것으로, 상기 아연은 산화아연 또는 글루콘산 아연의 형태일 수 있다.In addition, the vitamin A, vitamin D and zinc are essential nutrients for maintaining human health. They are taken together with lactic acid bacteria to increase the absorption rate thereof, and also help maintain the health of the consumers. The zinc is used as zinc oxide or zinc gluconate Lt; / RTI >
본 발명에서는 상기 혼합 유산균 10~20중량%, 바실러스 서브틸러스 0.1~1중량%, 프락토올리고당 10~15중량%, 갈락토올리고당 10~15중량%, 초유 20~30중량%, 비타민 A 0.01~0.05중량%, 비타민 D 0.0001~0.01중량%, 아연 0.1~0.5중량% 및 잔여분의 글루타민으로 배합되는 것이 바람직한바, 이는 각 성분의 작용을 고려한 것이다.In the present invention, it is preferable that 10 to 20% by weight of the mixed lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, 10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% To 0.05% by weight of vitamin D, 0.0001% to 0.01% by weight of vitamin D, 0.1% to 0.5% by weight of zinc and the remaining amount of glutamine.
이때, 상기 혼합 유산균은, 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)은 균수가 각각, 즉 11종 각각의 균수가 1.0×1011cfu/g~5.0×1011cfu/g인 것이 바람직한바, 그 균수가 상기한 범위보다 적으면 장내 환경 개선의 효과가 떨어지기 때문이다.The mixed lactic acid bacteria may be selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium lactis and Bifidobacterium bifidum are preferably in the range of 1.0 × 10 11 cfu / g to 5.0 × 10 11 cfu / g, respectively, If it is less than the above-mentioned range, the effect of improving intestinal environment is deteriorated.
상기와 같은 건강보조식품은 그 제형을 한정하지 않는바, 의약적으로 수용한 염, 부형제, 보존제, 착색제, 교미제 등과 함께, 의약품 또는 식품의 제조분야에서의 공지의 방법에 의해, 음료, 과립, 정제, 캡슐제 등의 여러 형태로서 제품화할 수 있다. 여기에서, 담체, 부형제, 희석제로는 토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The above-mentioned health supplement food is not limited to the formulations, and it may be formulated into various forms such as beverages, granules, preservatives, preservatives, coloring agents, , Tablets, capsules, and the like. Examples of the carrier, excipient and diluent include tosse, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Vaginal cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한, 본 발명에 따른 건강보조식품의 섭취량은 제한하지 않는바, 섭취자의 체중, 연령, 성별에 따라 다르지만, 5~20g/1일 정도일 수 있으며, 당업자에 의해 적절하게 선택될 수 있다.In addition, the amount of the health supplement food according to the present invention is not limited and may vary depending on the weight, age and sex of the recipient, but may be about 5 to 20 g / day, and may be appropriately selected by those skilled in the art.
한편, 본 발명에 따른 건강보조식품은 아밀라아제 0.5~3중량%, 리파아제 0.5~3중량%, 프로테아제 0.5~3중량%, 락토아제 0.5~3중량%를 더 포함할 수 있는바, 이러한 소화 효소를 더 포함하면 영양소가 흡수되는 것을 도와 신체의 대사작용 속도를 정상적으로 만들어준다. 따라서, 유산균과 함께 이러한 소화 효소를 더 포함하면 음식물의 분해속도가 빨라져 장내 환경이 더욱 빠르게 개선할 수 있다.Meanwhile, the health supplement food according to the present invention may further comprise 0.5-3% by weight of amylase, 0.5-3% by weight of lipase, 0.5-3% by weight of protease and 0.5-3% by weight of lactose, The inclusion of more nutrients helps to absorb the body's metabolic rate normally. Therefore, the inclusion of these digestive enzymes together with lactic acid bacteria accelerates the degradation rate of the food, and the intestinal environment can be improved more rapidly.
이하, 구체적인 실시예를 통해 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail with reference to specific examples.
(실시예 1)(Example 1)
락토바실러스 플란타럼(Lactobacillus plantarum MG208), 락토바실러스 애시도필러스(Lactobacillus acidophilus MG501), 락토바실러스 람노서스(Lactobacillus rhamnosus MG315), 락토바실러스 카제이(Lactobacillus casei MG311), 락토바실러스 파라카제이(Lactobacillus paracasei MG310), 락토바실러스 루테리(Lactobacillus reuteri MG505), 락토바실러스 살리바리우스(Lactobacillus salivarius MG595), 비피도박테리움 롱검(Bifidobacterium longum MG723), 비피도박테리움 브레브(Bifidobacterium breve MG729), 비피도박테리움 락티스(Bifidobacterium lactis MG740) 및 비피도박테리움 비피덤(Bifidobacterium bifidum MG720)의 유산균을 각각 배양하고, 그 배양액에 부형제로서 덱스트린을 배양액 중량의 1배만큼 첨가한 후 믹서로 분산하고, 이를 동결 분무건조시켜 파우더로 제조하였다. 각 파우더의 균수는 1.0×1011cfu/g~5.0×1011cfu/g의 범위였다. 그리고 상기 11종의 유산균 파우더를 모두 동일한 양으로 혼합하였다.Lactobacillus plantarum MG208, Lactobacillus acidophilus MG501, Lactobacillus rhamnosus MG315, Lactobacillus casei MG311, and Lactobacillus paracasei. paracasei MG310, Lactobacillus reuteri MG505, Lactobacillus salivarius MG595, Bifidobacterium longum MG723, Bifidobacterium breve MG729, Bifidobacterium, Lactic acid bacteria of Bifidobacterium lactis MG740 and Bifidobacterium bifidum MG720 were respectively cultured and dextrin as an excipient was added in an amount of 1 times the weight of the culture medium and dispersed in a mixer, And dried to prepare powder. The number of bacteria in each powder ranged from 1.0 × 10 11 cfu / g to 5.0 × 10 11 cfu / g. The 11 types of lactic acid bacteria powder were mixed in the same amount.
또한, 바실러스 서브틸러스(Bacillus subtillis)를 배양하고, 그 배양액에 부형제로서 덱스트린을 배양액 중량의 1배만큼 첨가한 후 믹서로 분산하고, 이를 동결 분무건조시켜 파우더로 제조하였다. 제조한 파우더의 균수는 1.0×1011cfu/g~5.0×1011cfu/g의 범위였다. In addition, Bacillus subtillis was cultured, dextrin as an excipient was added in an amount of 1 times the weight of the culture medium, and the mixture was dispersed with a mixer, and the mixture was freeze-spray-dried to prepare a powder. The number of bacteria in the powder was in the range of 1.0 × 10 11 cfu / g to 5.0 × 10 11 cfu / g.
다음으로, 상기 제조된 혼합 유산균 파우더 17.5량%, 바실러스 서브틸러스 파우더 1중량%, 프락토올리고당 13중량%, 갈락토올리고당 13중량%, 초유 25중량%, 비타민 A 0.02중량%, 비타민 D 0.001중량%, 글루콘산 아연 0.3중량% 및 잔여분의 글루타민을 혼합하였다.Next, 17.5% by weight of the prepared mixed lactic acid bacteria powder, 1% by weight of Bacillus subtilis powder, 13% by weight of fructooligosaccharide, 13% by weight of galactooligosaccharide, 25% by weight of colostrum, 0.02% by weight of vitamin A, , 0.3% by weight of zinc gluconate, and the remaining glutamine.
(시험예 1)(Test Example 1)
생후 4주된 ICR 마우스 10마리에 상기 실시예 1과 같이 제조된 조성물 150mg/kg을 정제수에 타서 하루에 1회 경구적으로 투여하였다. 실험 동물은 온도 20±2℃, 습도 40~60%, 명암 사이클 12시간의 조건에서 사육하였으며, 사료량 및 음수의 양은 제한하지 않았다.150 mg / kg of the composition prepared as in Example 1 was administered orally to 10 mice of 4 week old ICR mice once a day in purified water. The experimental animals were kept at 20 ± 2 ℃, 40 ~ 60% humidity and 12 hours of light cycle.
대조군 역시 실험군과 동일 조건에서 생후 4주된 ICR 마우스 10마리를 사육하되, 실시예 1의 조성물을 제공하지 않았다. In the control group, 10 ICR mice at 4 weeks of age were bred under the same conditions as the experimental group, but the composition of Example 1 was not provided.
(시험예 1-1)(Test Example 1-1)
분변 내의 유산균 수치 측정.Measurement of lactic acid bacteria in feces.
마우스의 분변 샘플을 수집한 후, 분변 샘플 0.1g을 마이크로 초음파 파쇄기(micro sonicator)로, 0.9ml의 0.1M phosphate buffer(pH 6.8 containing 0.5% cysteine)를 사용해서 현탁시키고, 상기 현탁액 중 0.2ml을 취해서 10-1부터 10-7까지 10분의 1로 연속 희석(series dilution) 시킨 후, MRS agar 플레이트 위에 0.1ml를 스프레드시켰다.After collecting the fecal samples of the mice, 0.1 g of the fecal sample was suspended in 0.9 ml of a 0.1 M phosphate buffer (pH 6.8 containing 0.5% cysteine) with a micro sonicator and 0.2 ml of the suspension After serial dilution of 10-1 to 10-7 in a volume of 1: 10, 0.1 ml was spread on an MRS agar plate.
상기 플레이트를 48시간 동안 혐기 상태(Bactron Anaerobic Chamber, Sheldon MFG. Inc., USA)에서 배양시킨 후, 콜로니들의 숫자를 장내 유산균 수치(number of fecal LAB)로 간주하였다.The plate was incubated for 48 hours in an anaerobic state (Bactron Anaerobic Chamber, Sheldon MFG. Inc., USA), and the number of colonies was then considered as the number of fecal LAB.
그 결과는 도 1에 나타내었다.The results are shown in Fig.
첨부된, 도 1에서 확인할 수 있는 바와 같이, 마우스의 분변 내 유산균 수치가 증가하였음을 확인할 수 있었다. 이는 장내 유산균의 총균수가 증가하였음을 의미하는 것이다.As can be seen from Fig. 1 attached, it was confirmed that the levels of lactic acid bacteria in the feces of the mice were increased. This means that the total number of lactic acid bacteria in the intestines was increased.
(시험예 1-2)(Test Example 1-2)
장내 유해효소 억제 효과 측정Measurement of inhibitory effect of intestinal harmful enzyme
마우스의 분변 샘플을 수집한 후, 분변 중 남아 있는 장내 세균에서 기인한 유해 효소의 활성을 측정하였다. 상기 분변은 시험예 1-1과 동일하게 현탁시켰다.Fecal samples of the mice were collected and the activity of the harmful enzymes resulting from intestinal bacteria remaining in the feces was measured. The feces were suspended in the same manner as in Test Example 1-1.
β-β- 글루코시다제Glucosidase 활성 측정 Active measurement
2 mM p-nitrophenyl-β-D-glucopyranoside 0.8ml와 현탁된 분변 샘플 0.2 ml로 구성된 반응액 1ml를 37℃에서 30분간 반응시킨 후, 0.5N NaOH 1ml를 첨가하여 반응을 종결시켰다. 반응이 종결된 반응 용액을 3,000rpm에서 10분간 원심 분리시킨 후, 상등액을 405nm에서 흡광도를 측정하였다.1 ml of a reaction solution consisting of 0.8 ml of 2 mM p-nitrophenyl-β-D-glucopyranoside and 0.2 ml of the suspended fecal sample was reacted at 37 ° C. for 30 minutes and then 1 ml of 0.5 N NaOH was added to terminate the reaction. After the reaction solution was centrifuged at 3,000 rpm for 10 minutes, the supernatant was measured for its absorbance at 405 nm.
β-β- 글루코니다제Gluconidase 활성 측정 Active measurement
2mM p-nitrophenyl-β-D-glucuronide 0.8ml와 현탁된 분변 샘플 0.2ml로 구성된 반응액 1ml를 37℃에서 30분간 반응시킨 후, 0.5N NaOH 1ml를 첨가하여 반응을 종결시켰다. 반응이 종결된 반응이 종결된 반응 용액을 3,000rpm에서 10분간 원심 분리시킨 후, 상등액을 405nm에서 흡광도를 측정하였다.1 ml of a reaction mixture consisting of 0.8 ml of 2 mM p-nitrophenyl-β-D-glucuronide and 0.2 ml of the suspended fecal sample was reacted at 37 ° C. for 30 minutes and then 1 ml of 0.5 N NaOH was added to terminate the reaction. After completion of the reaction, the reaction solution was centrifuged at 3,000 rpm for 10 minutes, and then the absorbance of the supernatant was measured at 405 nm.
트립토판나제Tryptophanase 활성 측정 Active measurement
complete reagent solution(0.05M potassium phosphate buffer 100ml에 2.75 mg of pyridoxal phosphate, 19.6mg of disodium EDTA dihydrate, 10mg of bovine serum albumin이 포함, pH 7.5) 0.2ml 및 20mM 트립토판 0.2ml, 현탁된 분변 샘플 0.1ml로 구성된 반응 용액을 37℃에서 1시간 동안 배양하고, color reagent 2ml를 첨가하여 반응을 종결시켰다. 반응이 멈춘 반응 용액을 3,000rpm에서 10분간 원심 분리시키고, 상등액을 550nm에서 흡광도를 측정하였다.0.2 ml of complete reagent solution (pH 7.5, containing 2.75 mg of pyridoxal phosphate, 19.6 mg of disodium EDTA dihydrate, and 10 mg of bovine serum albumin in 100 ml of 0.05 M potassium phosphate buffer), 0.2 ml of 20 mM tryptophan and 0.1 ml of suspended fecal sample The resulting reaction solution was incubated at 37 ° C for 1 hour, and 2ml of color reagent was added to terminate the reaction. The reaction solution in which the reaction was stopped was centrifuged at 3,000 rpm for 10 minutes, and the supernatant was measured for absorbance at 550 nm.
그리고 그 결과를 하기 표 1에 나타내었다.The results are shown in Table 1 below.
(%)activity
(%)
상기 표 1에서 확인할 수 있는 바와 같이, 실시예 1의 조성물 섭취 후 장내 유해 효소인 β-글루코시다제, β-글루코니다제, 트립토판나제의 활성이 현저히 감소함을 확인하였다.As can be seen from the above Table 1, it was confirmed that the activities of β-glucosidase, β-glucosidase, and tryptophanase, which are intestinal toxic enzymes, after ingestion of the composition of Example 1 were significantly reduced.
(시험예 2)(Test Example 2)
변비 환자 40명의 지원자를 모집하고, 지원자들에게 실시예 1의 조성물을 하루 1회, 7g씩 2주간 섭취하도록 하였으며, 2주 후 자신의 배변의 상태를 확인하여 설문지에 작성되어 있는 배변 상태의 6단계(‘물과 같다’, ‘묽다’, ‘부드럽다’, ‘보통이다’, ‘조금 딱딱’, ‘돌 같다’) 중 하나를 체크하도록 하였다.40 volunteers were recruited and volunteers were given 7 g of the composition of Example 1 once a day for 2 weeks. After 2 weeks, the condition of their defecation was checked and the defecation state of 6 I checked one of the stages ('like water', 'thinner', 'soft', 'normal', 'little crackle', 'stoned').
비교예로서, 변비 환자 40명의 지원자들을 모집하고, 젖당(lactose)만을 하루에 1회, 7g씩 2주간 섭섭취하도록 하였으며, 2주 후 자신의 배변의 상태를 확인하여 설문지에 작성되어 있는 배변 상태의 6단계(‘물과 같다’, ‘묽다’, ‘부드럽다’, ‘보통이다’, ‘조금 딱딱’, ‘돌 같다’) 중 하나를 체크하도록 하였다.As a comparative example, 40 volunteers were recruited and lactose was administered once a day, 7 g each for 2 weeks. After 2 weeks, the state of their defecation was checked. , And to check one of the six steps ('water like', 'thinning', 'soft', 'normal', 'little crackle', 'stone like').
그 결과를 하기 표 2에 나타내었다.The results are shown in Table 2 below.
상기 표 2에서 확인할 수 있는 바와 같이, 시험예는 변의 상태가 개선되어 변비가 개선됨을 확인할 수 있었으나, 젖당만을 섭취한 비교예는 변의 상태 변화가 거의 없었음을 확인하였다.As can be seen from the above Table 2, it was confirmed that the test case improved the condition of the side to improve the constipation, but it was confirmed that there was almost no change in the side condition in the case of the lactose alone.
이상, 본 발명을 바람직한 실시예를 사용하여 상세히 설명하였으나, 본 발명의 범위는 특정 실시예에 한정되는 것은 아니며, 첨부된 특허청구범위에 의하여 해석되어야 할 것이다. 또한, 이 기술분야에서 통상의 지식을 습득한 자라면, 본 발명의 범위에서 벗어나지 않으면서도 많은 수정과 변형이 가능함을 이해하여야 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the scope of the present invention is not limited to the disclosed exemplary embodiments. It will also be appreciated that many modifications and variations will be apparent to those skilled in the art without departing from the scope of the invention.
Claims (4)
상기 혼합 유산균은 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)인 것을 특징으로 하는 유산균 함유 건강보조식품.
Lactic acid bacteria, Bacillus subtillis, fructooligosaccharides, galactooligosaccharides, colostrum, glutamine, vitamin A, vitamin D and zinc,
The mixed lactic acid bacteria may be selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracase, paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis (Bifidobacterium lactis), Bifidobacterium lactis ) And Bifidobacterium bifidum. ≪ RTI ID = 0.0 > 18. < / RTI >
상기 혼합 유산균 10~20중량%, 바실러스 서브틸러스 0.1~1중량%, 프락토올리고당 10~15중량%, 갈락토올리고당 10~15중량%, 초유 20~30중량%, 비타민 A 0.01~0.05중량%, 비타민 D 0.0001~0.01중량%, 아연 0.1~0.5중량% 및 잔여분의 글루타민을 포함하는 것을 특징으로 하는 유산균 함유 건강보조식품.
The method according to claim 1,
10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% by weight of colostrum, 0.01 to 0.05% by weight of vitamin A, 10 to 20% by weight of lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, %, Vitamin D 0.0001 ~ 0.01 wt%, zinc 0.1 ~ 0.5 wt%, and the balance of glutamine.
락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)의 균수는 각각 1.0×1011cfu/g~5.0×1011cfu/g인 것을 특징으로 하는 유산균 함유 건강보조식품.
3. The method of claim 2,
Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus spp., Lactobacillus spp., Lactobacillus spp., Lactobacillus spp. Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium lactis, and Bifidobacterium lactis, Wherein the number of bacteria of Bifidobacterium bifidum is 1.0 x 10 11 cfu / g to 5.0 x 10 11 cfu / g, respectively.
아밀라아제 0.5~3중량%, 리파아제 0.5~3중량%, 프로테아제 0.5~3중량%, 락토아제 0.5~3중량%를 더 포함하는 것을 특징으로 하는 유산균 함유 건강보조식품.The method of claim 3,
A health supplement containing lactic acid bacteria, characterized by further comprising 0.5 to 3% by weight of amylase, 0.5 to 3% by weight of lipase, 0.5 to 3% by weight of protease, and 0.5 to 3% by weight of lactose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160119444A KR101847154B1 (en) | 2016-09-19 | 2016-09-19 | Health supplementary food containing lactic acid bacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160119444A KR101847154B1 (en) | 2016-09-19 | 2016-09-19 | Health supplementary food containing lactic acid bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180031247A true KR20180031247A (en) | 2018-03-28 |
KR101847154B1 KR101847154B1 (en) | 2018-04-09 |
Family
ID=61901442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160119444A KR101847154B1 (en) | 2016-09-19 | 2016-09-19 | Health supplementary food containing lactic acid bacteria |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101847154B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108785331A (en) * | 2018-08-10 | 2018-11-13 | 泰安大凡神农生物有限公司 | It is a kind of that there is qi-blood tonifying composition and its preparation method and application |
CN110464741A (en) * | 2019-02-25 | 2019-11-19 | 山东中微众康生物科技有限公司 | A kind of lactic acid bacteria oral liquor and preparation method thereof improving human body intestinal canal health |
KR20230001021A (en) * | 2021-06-24 | 2023-01-04 | 농업회사법인경주로칼푸드㈜ | A process for the preparation of cinnamon punch containing lactobacillus and the cinnamon punch containing lactobacillus prepared therefrom |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102155235B1 (en) | 2020-01-13 | 2020-09-11 | 주식회사 뉴팜 | Functional food |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1446023B1 (en) * | 2001-11-12 | 2009-02-25 | Mars, Incorporated | Foodstuff for cats and dogs |
JP2014079208A (en) * | 2012-10-17 | 2014-05-08 | Ryozo Saito | Supplement for improving intestinal environment and intestinal tract barrier |
JP5692549B2 (en) * | 2013-09-18 | 2015-04-01 | 株式会社東洋新薬 | Composition for intestinal cell activation |
-
2016
- 2016-09-19 KR KR1020160119444A patent/KR101847154B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108785331A (en) * | 2018-08-10 | 2018-11-13 | 泰安大凡神农生物有限公司 | It is a kind of that there is qi-blood tonifying composition and its preparation method and application |
CN108785331B (en) * | 2018-08-10 | 2020-07-17 | 泰安大凡神农制药有限公司 | Composition with qi and blood tonifying function and preparation method and application thereof |
CN110464741A (en) * | 2019-02-25 | 2019-11-19 | 山东中微众康生物科技有限公司 | A kind of lactic acid bacteria oral liquor and preparation method thereof improving human body intestinal canal health |
KR20230001021A (en) * | 2021-06-24 | 2023-01-04 | 농업회사법인경주로칼푸드㈜ | A process for the preparation of cinnamon punch containing lactobacillus and the cinnamon punch containing lactobacillus prepared therefrom |
Also Published As
Publication number | Publication date |
---|---|
KR101847154B1 (en) | 2018-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sanchez et al. | Probiotic fermented milks: present and future | |
Gupta et al. | Probiotics | |
Kailasapathy et al. | Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. | |
CA2774557C (en) | Lactobacillus plantarum strains as hypocholesterolemic agents | |
KR102141608B1 (en) | Composition comprising n-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity | |
EP1816190B1 (en) | New lactic bacteria useful as probiotics | |
EP2270133B1 (en) | Method for obtaining a novel strain of bifidobacterium bifidum with activity against infection by helicobacter pylori | |
KR101847154B1 (en) | Health supplementary food containing lactic acid bacteria | |
JP2014512376A (en) | Composition comprising probiotic bacteria capable of restoring the gastric barrier effect lost during pharmacological treatment of gastric hyperacidity | |
Papizadeh et al. | Lactobacillus rhamnosus Gorbach-Goldin (GG): A top well-researched probiotic strain | |
ITRM20110475A1 (en) | BACTERIA OF LACTIC AND / OR BIFIED BACTERIA BACTERIA, OPTIONALLY ADDED TO N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTETTO, HAVING INHIBITION ACTIVITIES / REDUCTION OF THE GROWTH OF DIFFERENT E.COLI BIOTYPES, INCLUDING E.COLI O157: H7 E | |
CN113474447A (en) | Strains, compositions and methods of use | |
GB2418431A (en) | Metabolically active micro organisms and methods for their production | |
KR101274467B1 (en) | Lactobacillus plantarum JBMI F5 strain having antibacterial activity against harmful bacteria and uses thereof | |
Kumar et al. | Bifidobacteria for life betterment | |
KR20220004865A (en) | Lactobacillus brevis SRCM101607 strain having probiotics-related enzyme secretion activity, antioxidant activity, Bile salt hydrolysis, antimicrobial activity, and not producing harmful enzyme and harmful metabolite and uses thereof | |
ES2264368B1 (en) | FOOD OR DIETETIC COMPLEMENT COMPOSED BY PRODUCTS FROM THE LIST OF MICROORGANISMS. | |
KR20020044046A (en) | A Nutraceuticals with various probiotics for treating intestinal disorders | |
Wang | Comparison of Microbial Quality of Commercial Probiotic Dietary Supplements | |
ES2262418B1 (en) | PROTEIN EXTRACTS WITH LARGE SPECTRUM OF ANTIBACTERIAL ACTIVITY AND BIFIDOBACTERIUM GENDER STRAINS THAT PRODUCE THEM. | |
Shaposhnikov et al. | Lactobacilli and Klebsiella: Two Opposites in the Fight for Human Health | |
Ashraf et al. | Assessment of probiotic potential and antagonistic characteristics of Bifidobacterium bifidum isolated from infant feces against enteropathogenic Escherichia coli | |
KR20240133902A (en) | Lacticaseibacillus paracasei strain PL1536 originated from Korean mother milk which has strong inhibitory activities on various pathogens as probiotics and the functional food composition containing it as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |